CELC.O Hits 52-Week High Amid Earnings Anticipation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 Nov 25
Source: investopedia.com
Shares of CELC.O surged today, reaching a new 52-week high as investors reacted positively to upcoming earnings reports from major companies, including Cisco Systems and Manulife Financial. The stock's breakout indicates strong bullish momentum, suggesting confidence in CELC's growth potential amidst a generally optimistic earnings season. Analysts are particularly focused on Cisco's expected earnings per share increase of 6.67% year-over-year, which may set a favorable tone for the market. Additionally, with Flutter Entertainment projecting a substantial 30.77% rise in earnings, investor sentiment remains buoyed, contributing to CELC's impressive performance.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 106.50 USD with a low forecast of 94.00 USD and a high forecast of 126.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 114.530
Low
94.00
Averages
106.50
High
126.00
Current: 114.530
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
